Autonomic dysfunction, Alzheimer’s disease, and the early signals we have not yet learned to hear.
This is Blog 2 of The Dysautonomia Journey — a fully referenced series following the autonomic dysfunction patient from their first clinical encounter to the structural patterns of the system that shapes their journey. Start with the Series Introduction if you’re new here.
In Blog 1, we mapped the full spectrum of dysautonomia — the many conditions that hide beneath the umbrella and the millions of people living within them. Today we go deeper. Because the autonomic nervous system does not only tell us about conditions like POTS or orthostatic hypotension. Increasingly, the evidence suggests it may be whispering something far more significant — a signal, often missed, often dismissed, that arrives years before the brain’s most devastating disease declares itself.
Alzheimer’s Disease: The Conversation We Think We Know
Alzheimer’s disease is the most common neurodegenerative disorder in the world, with more than 6.5 million Americans aged 65 and older currently affected — a number projected to rise to 12.7 million by 2050. Globally, Australia alone carries approximately 472,000 cases, with China carrying an estimated 17 million.
The conversation about Alzheimer’s disease in public discourse centres almost entirely on memory. But Alzheimer’s disease is not only a disease of memory. Its pathophysiology is multifactorial, involving amyloid-beta plaque accumulation, tau protein hyperphosphorylation, cholinergic deficits, oxidative stress, mitochondrial dysfunction, and cholesterol homeostasis disruption. And one of those systems — consistently implicated in its pathology from the earliest stages — is the autonomic nervous system.
The Overlooked Dimension: Dysautonomia in Alzheimer’s Disease
Autonomic nervous system dysfunction remains understudied in Alzheimer’s disease despite being common in the elderly. Four major potential causes for dysautonomia in Alzheimer’s disease have been identified — comorbidities, medication effects, Alzheimer’s pathology itself, and brain co-pathology — and dysautonomia in Alzheimer’s disease may enhance histopathological brain burden and accelerate neurodegenerative processes.
Although patients with Alzheimer’s disease rarely report dysautonomic symptoms spontaneously, they frequently exhibit abnormal results on autonomic tests — findings sufficient in some cases to differentiate Alzheimer’s disease patients from healthy controls and from patients with other forms of dementia. Given its impact on both quality of life and mortality, it is recommended that Alzheimer’s disease patients be systematically assessed for autonomic dysfunction.
The Cholinergic Thread That Connects Everything
The fundamental connection between autonomic dysfunction and Alzheimer’s disease runs through a single neurochemical thread: acetylcholine.
The control of cardiovascular and autonomic processes is largely dependent on the cholinergic system and its neurotransmitter acetylcholine. Right from the pre-clinical stage, Alzheimer’s disease notably affects this cholinergic system. Choline acetyltransferase activity is lowered to 35 to 50 percent of normal levels in Alzheimer’s disease, and synaptic reuptake of choline is decreased to 60 percent of normal levels.
This matters enormously. Acetylcholine is not only the neurotransmitter responsible for memory formation and cognitive function. It is the primary neurotransmitter of the parasympathetic nervous system — the system responsible for regulating heart rate, blood pressure, digestion, and the body’s capacity to rest, recover, and adapt. When acetylcholine production fails, the consequences cascade across both cognition and autonomic regulation simultaneously.
This is why the dysautonomia patient and the Alzheimer’s disease patient share more neurochemical territory than medicine has yet fully acknowledged — and why the signals the autonomic nervous system sends may be telling us something important about neurodegeneration long before the cognitive symptoms arrive.
Before the Diagnosis: Autonomic Dysfunction as an Early Signal
Perhaps the most clinically significant finding is what happens before established Alzheimer’s disease. Components of the central autonomic network attract the greatest neurofibrillary degeneration during Alzheimer’s disease. The insular cortex and brainstem are affected from the early stages. Autonomic dysfunction may be present prior to the onset of clinical symptoms.
People with mild cognitive impairment — the pre-dementia stage — are over five times more likely than controls to have autonomic dysfunction. Those with more significant autonomic dysfunction have more severe neuropsychological deficits. This relationship may accelerate cognitive decline via proinflammatory mechanisms and hypotension-induced cerebral hypoperfusion.
Sleep provides another compelling window. Studies have demonstrated that reduced slow-wave activity and autonomic dysfunction during sleep precede cognitive deficits in Alzheimer’s disease models — suggesting autonomic changes may play critical roles in preclinical Alzheimer’s disease before cognitive symptoms emerge.
Heart Rate Variability: A Biomarker at the Bedside
Autonomic dysfunction is an innovative biomarker of Alzheimer’s disease. Since cholinergic depletion invariably affects autonomic function parameters, the assessment of disease progression can be enhanced by analysing heart rate variability — a non-invasive, patient-friendly technique providing insights across time, frequency, and nonlinear domains.
Reduced heart rate variability, parasympathetic suppression, and sympathetic overactivity have all been documented in Alzheimer’s disease patients and correlate with disease severity. The Malmö Active Standing Test, which captures the full orthostatic heart rate profile including the initial overshoot and the 30:15 ratio, provides subtype-differentiating data that may prove valuable not only for dysautonomia diagnosis but as an early neurological risk indicator — accessible, non-invasive, and requiring nothing more than a watch and a blood pressure cuff.
The Stakes of Misattribution
The average patient with POTS waits six years and sees seven providers before receiving an appropriate diagnosis. 83 percent were initially misdiagnosed with a psychiatric condition. 59 percent were told their symptoms were all in their head. 69 percent were diagnosed with an anxiety disorder before receiving their correct diagnosis.
If autonomic dysfunction can precede the cognitive symptoms of Alzheimer’s disease by years or decades, and if the cholinergic deficit driving that autonomic dysfunction is the same deficit that cholinesterase inhibitors are designed to address, then the six-year diagnostic delay is not merely a quality-of-life issue.
It may be a neurological one.
Every year of that delay is a year in which the signal went unheard. A year in which the intervention that might have mattered was not offered. A year in which the nervous system was speaking — and the system built to listen was looking the other way.
Closing Thoughts
The autonomic nervous system does not operate in isolation. It is regulated by the same cholinergic circuits that fail in Alzheimer’s disease. It is assessed by the same bedside tools that measure early neurodegeneration. And its dysfunction, when recognised early rather than dismissed as anxiety, may represent precisely the kind of signal that gives us time to intervene.
The brain’s story does not begin at dementia. It begins in the whispers of a nervous system trying to tell us something long before the louder symptoms arrive. Learning to listen — in the clinic, at the research bench, and in every conversation about what dysautonomia really means — is one of the most important things medicine can do right now.
In Blog 3, we look at the precise moment this failure to listen begins — in the clinical encounter itself, in the words chosen to describe what the patient experiences, and in what those words cost them.
This blog is for educational purposes and does not constitute individual medical advice. Always consult a qualified healthcare professional regarding your health circumstances.
— Tracy Finnegan
Patient-Scientist | ICU Nurse 1991–2013 | UK · South Africa · Australia | IMB University of Queensland Directors Circle
References
Boris, J. R., Shadiack, E. C., III, McCormick, E. M., MacMullen, L., George-Sankoh, I., & Falk, M. J. (2024). Long-term POTS outcomes survey: Diagnosis, therapy, and clinical outcomes. Journal of the American Heart Association, 3, e033485. https://doi.org/10.1161/JAHA.123.033485
Dysautonomia International. (2013). Diagnostic delay in POTS. https://www.dysautonomiainternational.org/page.php?ID=184
Femminella, G. D., Rengo, G., Pagano, G., de Lucia, C., Komici, K., Bianco, A., & Leosco, D. (2014). Autonomic dysfunction in Alzheimer’s disease: Tools for assessment and review of the literature. Journal of Alzheimer’s Disease, 42(2), 369–377. https://doi.org/10.3233/JAD-140444
Guo, Z., Li, M., Magistretti, P. J., & Li, Q. (2025). Recent advances in Alzheimer’s disease. Signal Transduction and Targeted Therapy, 9, 243. https://doi.org/10.1038/s41392-024-01911-3
Novak, P., Gibbons, C., & Systrom, D. M. (2012). Parasympathetic autonomic dysfunction is common in mild cognitive impairment. Neurobiology of Aging, 33(12). https://doi.org/10.1016/j.neurobiolaging.2011.04.031
Raj, S. R. (2013). The postural tachycardia syndrome (POTS): Pathophysiology, diagnosis & management. Indian Pacing and Electrophysiology Journal, 13(3), 82–96. https://doi.org/10.1016/S0972-6292(16)30556-8
Tulba, D., Cozma, L., Popescu, B. O., & Davidescu, E. I. (2020). Dysautonomia in Alzheimer’s disease. Medicina, 56(7), 337. https://doi.org/10.3390/medicina56070337
Waseem, R., Bhatti, A., Ahmad, J., John, P., & Bhatti, M. (2023). Investigation of autonomic dysfunction in Alzheimer’s disease. Brain Sciences, 13(9), 1322. https://doi.org/10.3390/brainsci13091322 Zhang, L., Wang, Y., Li, H., & Ma, J. (2025). Dysautonomia in Alzheimer’s disease: A systematic review. Brain Sciences, 15(5), 502. https://doi.org/10.3390/brainsci15050502
